ARYx falls on tecarfarin data
This article was originally published in Scrip
Executive Summary
Disappointing Phase II/III data for ARYx Therapeutics' novel anticoagulant tecarfarin (formerly ATI-5923) have sent the Californian firm's share price tumbling.